TGFB1 and acute respiratory distress syndrome: Among survivors of ARDS secondary to COVID-19, individuals experiencing clinically relevant dyspnea at 6-months post-ICU discharge (mMRC ≥2) exhibited higher plasma TGF-β1 levels compared to the remained subjects (Figure 2A).